Tomassen Mathijs L, Pomp Jacquelien, van der Stap Janneke, van Lindert Anne S R, Peters Max, Belderbos José S A, De Ruysscher Dirk K M, Lin Steven H, Verhoeff Joost J C, van Rossum Peter S N
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Department of Pulmonology, University Medical Center Utrecht, the Netherlands.
Clin Transl Radiat Oncol. 2022 Feb 17;33:145-152. doi: 10.1016/j.ctro.2022.02.002. eCollection 2022 Mar.
Prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (LS-SCLC) patients has become more controversial. Since the publication of the systematic review by Aupérin et al. in 1999, no randomized controlled trials regarding PCI in LS-SCLC have been completed. The aim of this study was to systematically review and meta-analyze the effect of PCI on overall survival (OS) in patients with LS-SCLC.
A systematic search was conducted in the databases of MEDLINE (PubMed), Embase and the Cochrane library. Only studies that reported an adjusted hazard ratio (aHR), indicating the effect of PCI versus no PCI on OS (adjusted for confounders) in patients with LS-SCLC were included for critical appraisal and meta-analysis. A pooled aHR estimate was calculated using a random-effects model.
Pooling of 28 retrospective studies including a total of 18,575 patients demonstrated a significant beneficial effect of PCI versus no PCI on OS with a pooled aHR of 0.62 (95% CI: 0.57-0.69). Substantial heterogeneity of reported aHRs among studies was observed (I = 65.9%). Subgroup analyses revealed that this heterogeneity could partly be explained by study sample size. The pooled aHR among 7 versus 21 studies with a sample size of > 300 versus ≤ 300 patients was 0.79 (95% CI: 0.64-0.97) versus 0.56 (95% CI: 0.46-0.69; < 0.001), respectively.
This meta-analysis demonstrates a significant beneficial effect of PCI on OS in patients with LS-SCLC. Larger studies reported a milder beneficial effect, possibly due to a decreased risk of model overfitting. Serious risk of selection and confounding bias were of concern due to the lack of prospective trials. These results support the role of PCI in standard clinical practice in patients with LS-SCLC while awaiting results of prospective trials on alternative strategies.
对于局限期小细胞肺癌(LS-SCLC)患者,预防性颅脑照射(PCI)的争议越来越大。自1999年奥佩兰等人发表系统评价以来,尚未完成关于LS-SCLC患者PCI的随机对照试验。本研究的目的是系统评价和荟萃分析PCI对LS-SCLC患者总生存期(OS)的影响。
在MEDLINE(PubMed)、Embase和Cochrane图书馆数据库中进行系统检索。仅纳入报告了调整后风险比(aHR)的研究,该指标表明PCI与未进行PCI对LS-SCLC患者OS的影响(针对混杂因素进行了调整),用于关键评估和荟萃分析。使用随机效应模型计算合并的aHR估计值。
对28项回顾性研究(共纳入18575例患者)进行汇总分析,结果显示PCI与未进行PCI相比,对OS有显著有益影响,合并aHR为0.62(95%CI:0.57-0.69)。研究中报告的aHR存在显著异质性(I² = 65.9%)。亚组分析显示,这种异质性部分可由研究样本量来解释。样本量>300例与≤300例患者的7项研究与21项研究的合并aHR分别为0.79(95%CI:0.64-0.97)和0.56(95%CI:0.46-0.69;P<0.001)。
这项荟萃分析表明PCI对LS-SCLC患者的OS有显著有益影响。规模较大的研究报告的有益影响较温和,可能是由于模型过度拟合的风险降低。由于缺乏前瞻性试验,存在严重的选择和混杂偏倚风险。这些结果支持了PCI在LS-SCLC患者标准临床实践中的作用,同时等待替代策略前瞻性试验的结果。